Michael Findlay

Nepean Hospital — Australia

Medicine · Health Sciences

39h-index7.3kcitations172works11.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(55), Hepatocellular Carcinoma Treatment and Prognosis(27), Gastric Cancer Management and Outcomes(18), Cancer Treatment and Pharmacology(18), Pancreatic and Hepatic Oncology Research(17)

Publications168 total

In-house whole genome sequencing of multiply resistant bacteria by Oxford Nanopore to detect antimicrobial resistance genes: proof of concept
Pathology·2026
A thymine-challenge test to prospectively evaluate dihydropyrimidine dehydrogenase activity for risk of severe 5-fluorouracil-induced gastrointestinal toxicity
Cancer Chemotherapy and Pharmacology·2025Open Access
The younger women’s wellness after cancer program: results from feasibility testing in Aotearoa New Zealand (the ‘Kōwhai study’)
Supportive Care in Cancer·2025Open Access
Proton pump inhibition to prevent delayed chemotherapy-induced nausea and vomiting in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy: a phase II, randomised double-blind crossover trial (PantoCIN)
Supportive Care in Cancer·2025
Validation of multiplex lateral flow immunoassay NG-Test Carba 5 for the rapid identification of carbapenemase-producing organism
Pathology·2025
Preoperative Chemoradiotherapy for Resectable Gastric Cancer
New England Journal of Medicine·2024· 79 cited
LBA58 A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): Final results from an intergroup trial of AGITG, TROG, EORTC and CCTG
Annals of Oncology·2024· 2 citedOpen Access
P675: IMATINIB THERAPY IN PREVIOUSLY UNTREATED CHRONIC MYELOID LEUKAEMIA PATIENTS WHO ACHIEVE MMR AFTER 12 MONTHS THERAPY WITH DASATINIB: A STRATEGY TO AVOID LONG TERM OFF TARGET TOXICITY
HemaSphere·2023· 1 citedOpen Access
Successful Use of Cefiderocol to Treat a Multidrug-resistant Stenotrophomonas maltophilia Ventilator-associated Pneumonia in an Extremely Preterm Neonate
The Pediatric Infectious Disease Journal·2023· 14 cited
Supplemental tables and figures from Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line <i>RAS</i> Wild-Type Metastatic Colorectal Cancer
2023Open Access
Data from Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line <i>RAS</i> Wild-Type Metastatic Colorectal Cancer
2023Open Access
Supplemental tables and figures from Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line <i>RAS</i> Wild-Type Metastatic Colorectal Cancer
2023Open Access
Data from Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line <i>RAS</i> Wild-Type Metastatic Colorectal Cancer
2023Open Access
A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma
Cancer Immunology Immunotherapy·2023· 18 citedOpen Access
Real‐world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first‐line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma
Asia-Pacific Journal of Clinical Oncology·2022· 3 cited
Protocol of trans-Tasman feasibility randomised controlled trial of the Younger Women’s Wellness After Breast Cancer (YWWACP) lifestyle intervention
Pilot and Feasibility Studies·2022· 2 citedOpen Access
Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand
ANZ Journal of Surgery·2022· 4 citedOpen Access
Testing for dihydropyrimidine dehydrogenase deficiency in New Zealand to improve the safe use of 5-fluorouracil and capecitabine in cancer patients.
PubMed·2021· 1 cited
Severe 5-Fluorouracil-Associated Gastrointestinal Toxicity Unexplained by Dihydropyrimidine Dehydrogenase Deficiency and Renal Impairment: Should We Be Investigating Other Elimination Pathways to Assess the Risk of 5-Fluorouracil Toxicity?
European Journal of Drug Metabolism and Pharmacokinetics·2021· 5 cited
Clinical characteristics and outcomes of <scp>COVID</scp>‐19 in a low‐prevalence, well resourced setting, Sydney, Australia
Internal Medicine Journal·2021· 6 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

David Cunningham(9), Peter Gibbs(7), Volker Heinemann(7), Val Gebski(7), Navesh Sharma(5), Julien Taı̈eb(5), Jens Ricke(5), Marc Peeters(5), Pierce K. H. Chow(5), Guy van Hazel(4), Stephen Clarke(4), Vinod Ganju(4), Andrew Strickland(4), Michael J. Solomon(4), Katrina Sharples(4), Harpreet Wasan(3), Jamie Mills(3), Ricky A. Sharma(3), Tamas Hickish(3), Matthew Burge(3)